Friday 18 July

09:00-10:40

Diagnosis and assessment
Chairs: Roger Francis/Paul Miller

09:00

IS9

ADVANCES IN IMAGING TECHNIQUES

Ignac Fogelman (London, UK)

09:20

IS10

PREDICTION AND ASSESSMENT OF RESPONSE: BIOCHEMICAL ASSESSMENT

Bill Fraser (Liverpool, UK)

09:40

IS11

MR/CT IMAGING OF PAGET’S DISEASE OF BONE

Rick Whitehouse (Manchester, UK)

10:00

Oral communications
Chairs: Roger Francis/Paul Miller

10:00

18

18F-FLUORIDE POSITRON EMISSION TOMOGRAPHY: PRELIMINARY ASSESSMENT OF THERAPY IN PAGET'S DISEASE OF BONE

A T Nzeusseu^[1], M Lonneux^[2], G Depresseux^[1], J Installe^[2], J P Devogelaer^[1]. Departments of ^[1]Rheumatology; ^[2]Nuclear Medicine, St-Luc University Hospital, Université Catholique de Louvain, B-1200 Brussels, Belgium

10:08

19

COMPARATIVE RESPONSES OF 7 BONE TURNOVER MARKERS TO IBANDRONATE THERAPY IN PAGET'S DISEASE

I R Reid^[1], J S Davidson^[2], D Wattie^[1], F Wu^[1], J Lucas^[1], G D Gamble^[1], T Cundy^[1]. ^[1]Department of Medicine, University of Auckland, New Zealand; ^[2]Labplus, Auckland Hospital, New Zealand

10:16

20

THE STABILITY OF RANKL AND OPG IN HUMAN SERUM

B Y Y Chan^[1], K A Buckley^[2], B H Durham^[1], J Dutton^[1], J A Gallagher^[2], W D Fraser^[1]. ^[1]Department of Clinical Chemistry, Royal Liverpool University Hospital, The University of Liverpool, UK; ^[2]Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology, The University of Liverpool, UK

10:24

21

EFFECT OF RECOMBINANT HUMAN RANKL ON FORMATION OF OSTEOCLASTS: CORRELATION BETWEEN RELEASE OF BETA C-TERMINAL TELOPEPTIDES FROM DENTINE DISCS AND AREA OF RESORPTION

B Y Y Chan^[1], K A Buckley^[2], J Dutton^[1], J A Gallagher^[2], W D Fraser^[1]. ^[1]Department of Clinical Chemistry, Royal Liverpool University Hospital, The University of Liverpool, UK; ^[2]Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology, The University of Liverpool, UK

10:32

22

SERUM OSTEOPROTEGERIN AND SERUM RANKL IN PAGET'S DISEASE

G Martini, R Valenti, S Giovani, L Gennari, S Salvadori, B Galli, D Merlotti, R Nuti. Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy

10:40

Coffee and posters

11:00-12:40

Complications
Chairs: Ken Lyles/Michael Stone

11:00

IS12

RHEUMATOLOGICAL COMPLICATIONS OF PAGET’S DISEASE

Phil Helliwell (Leeds, UK)

11:20

IS13

HEARING IN PAGET’S DISEASE

Richard Ramsden (Manchester, UK)

11:40

IS14

ORTHOPAEDIC COMPLICATIONS OF PAGET'S DISEASE

Jimmy Hutchison (Aberdeen, UK)

12:00

Oral communications
Chairs: Ken Lyles/Michael Stone

12:00

23

CONCURRENT PAGET'S DISEASE OF BONE AND PRIMARY HYPERPARATHYROIDISM

C Leens, J P Devogelaer. Department of Rheumatology, Saint-Luc University Hospital, Université Catholique de Louvain, B-1200 Brussels, Belgium

12:08

24

FOOT PROBLEMS IN PAGET'S DISEASE

A Williams[1,3], T W O'Neill^[2], S Mercer ^[2], C J Nester^[3]. ^[1]Department of Podiatry, University of Salford, UK; ^[2]Department of Rheumatology, Hope Hospital, Salford, UK; ^[3] Centre for Rehabilitation and Human Performance Research, University of Salford, UK

12:16

25

HETEROTOPIC BONE FORMATION FOLLOWING HIP ARTHROPLASTY IN PAGET'S DISEASE

N A Athanasou, M Maki, I Itonaga, D Ferguson, E McNally, R Gundle. Nuffield Department of Orthopaedic Surgery & Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 7LD, UK

12:24

26

ACTIONS OF CHEMICALLY MODIFIED TETRACYCLINES ON OSTEOCLAST AND OSTEOBLAST LINEAGE CELLS IN VITRO

S G Holmes, K Still, D J Buttle, N J Bishop, P S Grabowski. Academic Unit of Child Health, University of Sheffield, UK

12:32

27

VITAMIN D3 ANTAGONISTS: A POTENTIAL TREATMENT FOR PAGET'S DISEASE

S Ishizuka[1,2], N Kurihara^[2], Y Harada^[1], K Takenouchi^[1], J Cornish^[3], T Condy^[3], S V Reddy^[2], G D Roodman[2,4]. ^[1]Teijin Institute for Bio-Medical Research, Tokyo, Japan; ^[2]University of Pittsburgh Medical Center, USA; ^[3]University of Auckland, New Zealand; ^[4]VA Medical Center, Pittsburgh, USA

12:40

Lunch and posters

14:00-17:15

Treatment
Chairs: Jean-Pierre Devogelaer/Richard Eastell

14:00

IS15

PRE-CLINICAL EVALUATION OF BISPHOSPHONATES

Jonathan Green (Basle, Switzerland)

14:30

IS16

COMPARISON OF UK AND US PRACTICE AND GUIDELINES

IS17

Peter Selby (Manchester, UK)/Ethel Siris (New York NY, USA)

15:10

Oral communications
Chairs: Jean-Pierre Devogelaer/Richard Eastell

15:10

28/29

THE PRISM TRIAL: A RANDOMISED TRIAL OF INTENSIVE VS SYMPTOMATIC MANAGEMENT FOR PAGET'S DISEASE OF THE BONE AND THE PRISM TRIAL: A DNA REPOSITORY SUB-STUDY

A L Langston^[1], S H Ralston^[2], M K Campbell^[1], W D Fraser^[3], P L Selby^[4] and the PRISM Trial Group. ^[1]Health Services Research Unit, University of Aberdeen, UK; ^[2]University of Aberdeen Medical School, Institute of Medical Sciences, UK; ^[3]Department of Clinical Chemistry, The University of Liverpool, UK;  ^[4]University of Manchester Department of Medicine, Manchester Royal Infirmary, UK

15:20

30

INTRAVENOUS PAMIDRONATE OR ORAL ALENDRONATE FOR THE TREATMENT OF PAGET'S DISEASE OF BONE: RESULTS OF A RANDOMISED CONTROLLED TRIAL

J P Walsh^[1,4], G O Stewart^[2], R K Will^[3], R A Criddle^[5], R L Prince^[1,4], B G A Stuckey^[1], L C Ward^[1], S S Dhaliwal^[1],  P Drury^[7], C I Bhagat^[6], R W Retallack^[1], G N Kent^[6], S Vasikaran^[8], D H Gutteridge^[1]. ^[1]Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[2]Department of Endocrinology & Diabetes, Fremantle Hospital, WA, Australia; ^[3]Department of Rheumatology, Royal Perth Hospital, WA, Australia; ^[4]Department of Medicine, University of Western Australia, Australia; ^[5]Department of Rehabilitation & Aged Care, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[6]PathCentre, Nedlands, WA, Australia; ^[7]Department of Radiology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ^[8]Department of Biochemistry, Royal Perth Hospital, Australia

15:28

31

COMPARISON OF CLINICAL EFFECTS OF ORAL RISEDRONATE AND INTRAVENOUS PAMIDRONATE IN PATIENTS WITH PAGET'S DISEASE OF BONE

S B Seechurn, M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK.

15:36

32

ZOLEDRONIC ACID IN THE MANAGEMENT OF PAGET'S DISEASE OF BONE

S Harrison, M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK

15:48

Tea

16:15

Treatment controversies
Chairs: Michael Davie/Michael Davies

16:15

33

INTRAVENOUS ZOLEDRONIC ACID FOR TREATING

INTRACTABLE PAGET'S DISEASE OF BONE

C Moniz, T Mangion, R Chandra. Metabolic Bone Clinic, Clinical Biochemistry, Kings College Hospital, London, UK

16:25

34

DO WE GIVE TOO MUCH BISPHOSPHONATE FOR PAGET'S DISEASE OF BONE?

M Davies, P L Selby. University Department of Medicine, Manchester Royal Infirmary, UK

16:35

35

RESPONSIVENESS-RESISTANCE- AND RE-RESPONSIVENESS TO PAMIDRONATE IN A PATIENT WITH PAGET’S DISEASE OF THE VERTEBRAL BODY

P Miller. Colorado Center for Bone Research, Colorado, USA

16.45

Clinical problems in Paget's Disease: cases for discussion
Chairs: Michael Davie/Michael Davies

17:15

Break

17:30

Keynote lecture
Chairs: Marilyn McCallum/Graham Russell

Sir Julian Paget

18:00

End